PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab

BackgroundNon-small cell lung cancer (NSCLC) patients with high expression of PDL1 are more likely to benefit from atezolizumab. There no relevant research focusing on the relationship between and clinical variables gene mutation types among NSCLC patients.MethodsNSCLC confirmed information OAK study were included in our study. Logistic regression proportional model was applied analyze risk factors expression. The biomarker evaluable population (BEP) screened informaion these patients. High frequency mutations based different expressions. Moreover, log rank test overall survival (OS) difference types.ResultsA total 838 White have ? 1% (P = 0.004). ERBB4, EP300, PREX2, SLIT2, EPHB1 IGF2R expression, EGFR, SMARCA4, EPHA5, FAT1, STK11, TET2 be seen negative group. Worse could found KEAP1 < 0.001), TP53 0.004) EPHA5 0.013) who received atezolizumab compared those had none mutations. Importantly, for without KEAP1, receiving atezolizumab, they all showed relatively longer median 22.47, 22.18 23.33 months, respectively (all, P 0.01).ConclusionsDifferent PDL1. combined specific may better predict